Most recently, the HIMALAYA trial evaluated a single priming dose of the anti-CTLA-4 inhibitor tremelimumab 300 mg daily combined with the anti-PD-L1 agent durvalumab 1,500 mg every 4 weeks in patients with unresectable HCC. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.